Journal · Updated 2026-08-11
ShedRx Review 2026: Four Formats, a 45% Dose Spread, and an Affiliate First-Month Discount
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
ShedRx is the format maximalist: per July 2026 captures, compounded semaglutide injection from two forty-nine, GLP-1 lozenges from one ninety-nine, liquid drops from two twenty-nine, oral liposomal tablets from two ninety-nine, and tirzepatide injection carrying a start-near-one-ninety-nine, maintain-near-two-eighty-nine structure — the forty-five percent dose spread our Teaser Index measured — plus an affiliate-routed thirty-percent first-month discount whose recurring price applies from month two. Two findings coexist: the menu breadth is real (four delivery formats is the widest we track), and so is the pattern — the cheapest entries are the least-proven routes, the proven injectable carries dose-anchored pricing, and the promo is first-month plumbing, not a rate.
The menu, the spread, and the questions
Ranked on proven-route maintenance, ShedRx sits upper-mid: two eighty-nine tirzepatide is a hundred-ten over the flat tier and within sight of brand vials; two forty-nine semaglutide injection is a hundred-twenty over bmiMD. The alternative formats price lower and carry the standing route caveat — lozenges, drops, and liposomal oral semaglutide have no approved counterparts and no pivotal trials, making them distinct products at tempting prices rather than cheaper versions of the same one. The dose spread converts to the usual question set: my dose's maintenance rate in writing; the escalation schedule and its prices; the recurring rate after the affiliate month; the pharmacy name. Higher-dose pricing and exact formulation, our records note, warrant confirmation before checkout — which is the polite version of "the menu's fine print is the menu."
Verdict
ShedRx fits the buyer who specifically wants format optionality under one roof and will do the four-question diligence — understanding that the evidence-backed format is the expensive one, and that at two eighty-nine maintaining, the FDA-approved vial at two ninety-nine-to-four forty-nine is the comparison that decides most cases. For the price-first buyer, the flat-rate tier does the same injectable job for a hundred-plus less monthly; for the needle-averse, the one forty-nine FDA-approved oral Wegovy tablet outranks every unproven format on the menu. The menu is the moat; make sure it's the moat you need.
Questions people ask
How much does ShedRx cost?
July 2026 captures: semaglutide injection from $249; lozenges $199; drops $229; oral liposomal tablets $299; tirzepatide injection starting near $199 with maintenance near $289 (a 45% dose spread). A 30% first-month affiliate discount exists; the recurring rate applies from month two.
Are ShedRx's lozenges and drops as effective as injections?
Unproven: no approved lozenge, drop, or liposomal-oral GLP-1 exists, and no pivotal trials back those routes. They're distinct products at lower prices — evaluate them as such. For needle-free with evidence, FDA-approved oral Wegovy ($149) is the benchmark.
Why does ShedRx tirzepatide cost more at higher doses?
Dose-anchored pricing: the ~$199 entry reflects starter doses, with maintenance near $289 — the 45% spread our index measured. Get your dose's rate and the escalation schedule in writing before subscribing; flat-at-every-dose programs ($169–$179) exist if the spread bothers you.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.